Most people diagnosed with subclinical hypothyroidism do not need immediate medication. The condition, defined by a mildly elevated TSH with normal thyroid hormone levels, resolves on its own in a large share of cases and only progresses to full-blown hypothyroidism in a minority. Whether and when to start levothyroxine depends on how high your TSH is, whether you have thyroid antibodies, your age, and whether pregnancy is in the picture. Getting those details right matters, because treating too early can be unnecessary while treating too late can mean preventable complications.
Confirm It Before You Treat It
A single elevated TSH reading is not enough to act on. Guidelines recommend repeating the blood test along with a free T4 measurement somewhere between two and twelve weeks later, depending on how high the initial value was and what else is going on clinically.1JAMA. Subclinical Thyroid Disease: Clinical Applications TSH fluctuates with time of day, season, illness, and stress. A single mildly elevated result can easily reflect a temporary blip rather than a persistent thyroid problem.
The data on how often subclinical hypothyroidism spontaneously corrects itself are striking. One large study found that about 60% of patients had normal TSH levels when retested at one year. Normalization was more common in younger patients, in women, in those whose initial TSH was only slightly above the upper limit, and in those retested during the summer months. Even in a second patient group with somewhat higher initial values, 40% normalized within a year without any treatment.2PubMed. TSH spontaneously normalizes in many older adults with subclinical hypothyroidism So if your TSH comes back mildly elevated once, the most important first step is simply to recheck it before committing to lifelong medication.
Who Is Likely to Get Worse
Not everyone who stays subclinically hypothyroid on repeat testing will eventually develop overt hypothyroidism. The two strongest predictors of progression are the TSH level itself and the presence of thyroid peroxidase (TPO) antibodies, which indicate that the immune system is attacking the thyroid gland.
A review in JAMA noted that patients with circulating TPO antibodies face a meaningfully greater risk of progressing from subclinical to overt hypothyroidism.3JAMA. Subclinical Hypothyroidism: A Review A prospective study put numbers to this: progression to overt thyroid failure occurred in about 59% of patients who had positive TPO antibodies, compared with roughly 23% of those who tested negative. Combining TSH level, antibody status, and a measure of thyroid reserve allowed researchers to stratify risk across a wide range.4The Journal of Clinical Endocrinology & Metabolism. Prospective Study of the Spontaneous Course of Subclinical Hypothyroidism: Prognostic Value of Thyrotropin, Thyroid Reserve, and Thyroid Antibodies In practical terms, if your TSH is persistently above 10, or you have positive TPO antibodies plus a TSH that keeps creeping up on repeat tests, the odds favor eventual progression, and that changes the calculus on treatment.
The TSH-Above-10 Threshold
The clearest consensus across international guidelines is that a persistently elevated TSH above 10 mIU/L in adults under 70 warrants treatment, especially when accompanied by heart disease, heart failure, or symptoms. The 2023 Korean Thyroid Association guidelines, which echo positions taken by the American and European thyroid societies, state that levothyroxine is necessary when subclinical hypothyroidism with a TSH above 10 is accompanied by coronary artery disease or heart failure, and that treatment can also be considered for improving abnormal cholesterol profiles.5Endocrinology and Metabolism. Management of Subclinical Hypothyroidism: A Focus on Proven Health Effects in the 2023 Korean Thyroid Association Guidelines
Below a TSH of 10, the picture gets murkier. Treatment in that mild range is generally not recommended as a blanket policy, but clinicians may consider it on a case-by-case basis when patients have symptoms they attribute to thyroid dysfunction, positive TPO antibodies, an enlarged thyroid gland, abnormal lipids, or reproductive concerns like infertility or recurrent miscarriage.6PubMed Central. Subclinical Hypothyroidism – Whether and When To Start Treatment?
Pregnancy and Fertility Change the Equation
Pregnancy is the one clinical context where the argument for treating subclinical hypothyroidism is strongest and most consistent. Thyroid hormones are critical for fetal brain development, and the mother’s thyroid has to work harder during pregnancy to meet both her own and the baby’s needs. A meta-analysis of pregnant women with subclinical hypothyroidism found that levothyroxine treatment was associated with a 45% lower risk of pregnancy loss, a 37% lower risk of preterm birth, and a 22% lower risk of gestational hypertension compared with untreated controls.7PubMed Central. Pregnancy and Neonatal Outcomes With Levothyroxine Treatment in Women With Subclinical Hypothyroidism Based on New Diagnostic Criteria: A Systematic Review and Meta-Analysis
For women undergoing in vitro fertilization, a small randomized trial found that levothyroxine improved embryo implantation rates and reduced miscarriage. The implantation rate was roughly 27% in the treated group versus 15% in controls, and miscarriage dropped to zero in the treated arm compared with about a third of pregnancies in the untreated group.8European Journal of Endocrinology. Levothyroxine supplementation trials in preconception and pregnant women These are small numbers, but the direction is consistent across studies.
Where the story gets less clear is whether treatment during pregnancy improves children’s cognitive outcomes. A large randomized trial found no significant difference in IQ scores between children whose mothers received levothyroxine and those whose mothers received placebo, with median scores of 97 and 94 respectively. No other neurocognitive or pregnancy outcomes differed either.9PubMed Central. Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy So the strongest pregnancy-related argument for treatment centers on reducing miscarriage and preterm delivery rather than boosting the child’s developmental scores. Most guidelines still recommend treatment during pregnancy given the obstetric benefits and the low risk of levothyroxine at appropriate doses.
From a cost standpoint, universal screening for subclinical hypothyroidism during pregnancy appears to pay for itself. A modeling study estimated that for every 100,000 pregnant women screened, screening saved over $8 million and produced nearly 590 quality-adjusted life years gained.10PubMed. The cost-effectiveness of universal screening in pregnancy for subclinical hypothyroidism
Older Adults Often Do Better Without Treatment
If pregnancy is where treatment helps the most, advanced age is where it helps the least. The TRUST trial, a large randomized controlled trial of 737 adults aged 65 and older with persistent subclinical hypothyroidism, found no benefit from levothyroxine on symptoms, quality of life, or any secondary outcome. At one year, hypothyroid symptom scores and tiredness scores were statistically indistinguishable between the treatment and placebo groups.11PubMed. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism A companion study in adults aged 80 and older confirmed the same pattern: levothyroxine made no difference in hypothyroid symptoms or tiredness compared with placebo at twelve months.12JAMA. Association Between Levothyroxine Treatment and Thyroid-Related Symptoms Among Adults Aged 80 Years and Older With Subclinical Hypothyroidism
Cardiovascular outcomes in older adults tell a similar story. A pooled analysis of two randomized trials in older patients found that levothyroxine did not significantly change the risk of cardiovascular events, atrial fibrillation, heart failure, or death from any cause.13PubMed Central. Levothyroxine Treatment and Cardiovascular Outcomes in Older People With Subclinical Hypothyroidism: Pooled Individual Results of Two Randomised Controlled Trials A separate randomized trial looking at heart function directly found no meaningful change in measures of how well the heart pumps or fills after levothyroxine therapy in older adults.14The American Journal of Medicine. Effect of Thyroid Hormone Therapy on Cardiac Function in Older Adults with Subclinical Hypothyroidism: A Randomized Controlled Trial
Given all of this, major guidelines now advise against treating mild subclinical hypothyroidism in people aged 70 and older, and they generally do not recommend treatment even for more elevated TSH values in the elderly unless there is a compelling individual reason.5Endocrinology and Metabolism. Management of Subclinical Hypothyroidism: A Focus on Proven Health Effects in the 2023 Korean Thyroid Association Guidelines The mild elevation in TSH that comes with aging may actually be physiologically normal rather than pathological.
Heart Risk Depends on Age
A key reason treatment guidelines differ by age is that the cardiovascular risk of subclinical hypothyroidism itself appears to be age-dependent. A meta-analysis of ten population-based cohort studies found that the overall risk of coronary heart disease with subclinical hypothyroidism was modestly elevated but not statistically significant when all ages were pooled together. The picture changed when the data were broken down by age: in studies where the average participant was younger than 65, the risk was about 50% higher, while in studies of older populations the risk was essentially no different from that of people with normal thyroid function.15PubMed. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality
A separate large observational analysis estimated that cardiovascular disease mediated about 14% of the association between subclinical hypothyroidism and all-cause mortality.16JAMA Network Open. Association of Subclinical Hypothyroidism and Cardiovascular Disease With Mortality This gives some biological plausibility to treating younger adults with more markedly elevated TSH, especially if they also carry other cardiovascular risk factors. But for older adults, the interventional data consistently fail to show that treatment translates into fewer heart attacks or longer life.
Cholesterol Improvements Are Real but Modest
One argument for treatment that holds up across age groups is the effect on LDL cholesterol. Multiple studies show that subclinical hypothyroidism is associated with elevated total cholesterol, LDL cholesterol, and apolipoprotein B, and that levothyroxine reverses those elevations. A randomized placebo-controlled study confirmed that LDL levels are specifically and reversibly elevated in subclinical hypothyroidism: levothyroxine brought LDL down significantly, while placebo did not.17The Journal of Clinical Endocrinology & Metabolism. Lipoprotein Profile in Subclinical Hypothyroidism: Response to Levothyroxine Replacement, a Randomized Placebo-Controlled Study Another placebo-controlled trial found that treatment reduced both LDL and a marker of early artery-wall thickening (intima-media thickness) by about 11%.18The Journal of Clinical Endocrinology & Metabolism. Effect of Levothyroxine Replacement on Lipid Profile and Intima-Media Thickness in Subclinical Hypothyroidism: A Double-Blind, Placebo-Controlled Study
Whether those lipid improvements translate into fewer heart attacks is harder to prove. The reduction in LDL is genuine and consistent, but as the previous section shows, the randomized trials of heart outcomes in older adults have been disappointing. In younger patients with high cardiovascular risk and stubbornly elevated LDL, the lipid benefit may tilt the decision toward treatment. In someone whose cholesterol is otherwise well-controlled, it matters less.
A broader study of hypothyroid patients (not limited to subclinical cases) similarly documented significant drops in total cholesterol, triglycerides, and LDL after levothyroxine, with no meaningful change in HDL.19PubMed Central. Investigating the effect of levothyroxine replacement on cholesterol levels in hypothyroid patients
Cardiac Function in Younger Patients
A systematic review and meta-analysis that included studies across a broader age range (not limited to elderly participants) found that levothyroxine did modestly improve certain measures of heart function, including cardiac output, ejection fraction, and a ratio reflecting how well the heart fills during relaxation.20The Journal of Clinical Endocrinology & Metabolism. Effect of Levothyroxine Supplementation on the Cardiac Morphology and Function in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis The improvements were statistically significant but small, and they are most relevant in younger adults whose cardiovascular system may be more responsive to thyroid hormone correction. They reinforce the idea that age matters when deciding whether treatment will do anything useful.
Risks of Overtreatment
Levothyroxine is one of the most commonly prescribed medications in the world, and it is generally safe at the right dose. The danger comes when a patient is overtreated, pushing TSH below normal into the hyperthyroid range. The most commonly documented consequences of overtreatment are cardiac arrhythmias, especially atrial fibrillation, and worsening of osteoporosis.21PubMed Central. Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery These are the same problems you would see in someone with an overactive thyroid, and they are particularly dangerous in older adults, which is another reason why treatment in the elderly requires a strong justification.
In subclinical hypothyroidism specifically, many patients start at low doses of 25 to 50 micrograms per day, with adjustments made based on follow-up TSH checks. Elderly patients, those with low body weight, and those with existing heart disease typically begin at the lower end.22PubMed. Getting the levothyroxine (LT4) dose right for adults with hypothyroidism: opportunities and challenges in the use of modern LT4 preparations The goal is to bring TSH into a normal range without overshooting. Regular monitoring, usually every six to eight weeks after a dose change and then every six to twelve months once stable, is part of the commitment.
What About Fatigue and Other Symptoms
Many people who learn they have subclinical hypothyroidism assume the condition is causing their fatigue, brain fog, or weight gain, and that treatment will fix those symptoms. The evidence is not encouraging on this front. The TRUST trial found zero difference in tiredness or hypothyroid symptom scores between treated and untreated older adults.11PubMed. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism That is consistent with the reality that many common symptoms overlap with dozens of other causes, from poor sleep to iron deficiency to depression. A mildly elevated TSH does not explain most people’s fatigue.
Surveys of patients on levothyroxine therapy suggest that dissatisfaction persists even when lab values normalize. The most common complaints among dissatisfied patients are fatigue, difficulty managing weight, cognitive problems, and mood issues.23The Journal of Clinical Endocrinology & Metabolism. Critical Approach to Hypothyroid Patients With Persistent Symptoms This does not mean levothyroxine fails across the board. Patients who had clear hypothyroid symptoms at the time of diagnosis tend to perceive greater benefit and maintain better adherence.24BJGP Open. Patients’ attitudes and perceptions towards treatment of hypothyroidism in general practice: an in-depth qualitative interview study But for someone whose subclinical hypothyroidism was picked up on routine bloodwork and who feels fine, starting levothyroxine is unlikely to produce a noticeable improvement in how they feel.
Children and Adolescents
Subclinical hypothyroidism in children follows a broadly similar framework to adults, with one key difference: growth and development are at stake. There is consensus that children with a TSH persistently above 10 should be treated.25PubMed Central. Subclinical hypothyroidism in children: updates for pediatricians For the mild form with TSH between about 4.5 and 10, most studies indicate that the condition frequently resolves on its own or persists without worsening. Current recommendations support treatment in children with a goiter, symptoms suggestive of hypothyroidism, or severe elevation, but not routine medication for all children with mild, asymptomatic subclinical hypothyroidism.26Journal of the Endocrine Society. Mild Hypothyroidism in Childhood: Who, When, and How Should Be Treated? Instead, regular monitoring of thyroid function and clinical examination is recommended so that a child who starts to progress can be caught early.
Testing Pitfalls Worth Knowing About
Before making any treatment decision, it is worth being aware that some supplements can produce misleadingly abnormal thyroid test results. Biotin, which is widely sold for hair and nail health and is included in many multivitamins, can interfere with the immunoassay technology used in standard thyroid panels. At high doses, biotin has been shown to create lab results that mimic thyroid disease even when thyroid function is normal. Case reports document patients whose results normalized completely after stopping biotin for a week.27PubMed Central. Effect of High-dose Biotin on Thyroid Function Tests: Case Report and Literature Review Doses of 20 mg or more appear to cause clinically relevant interference, but even lower doses in some assays can shift results.28PubMed Central. How Biotin Induces Misleading Results in Thyroid Bioassays: Case Series If you take biotin supplements, mention it to your doctor before thyroid testing, or stop taking them for at least two days before the blood draw.
Certain medications can also affect TSH levels independently of actual thyroid disease. Glucocorticoids, dopamine-related drugs, and some other medications can suppress TSH through effects on the brain’s signaling to the thyroid gland, potentially masking or mimicking thyroid conditions.29PubMed Central. Drugs that suppress TSH or cause central hypothyroidism Your full medication list matters when interpreting thyroid results.
Selenium and Other Nutritional Approaches
Selenium has attracted attention as a potential adjunct for subclinical hypothyroidism, particularly when autoimmune thyroiditis is the underlying cause. Selenium is a building block of several enzymes involved in thyroid hormone production and the antioxidant defense of thyroid cells.30Future Journal of Pharmaceutical Sciences. Zinc and selenium in the management of subclinical hypothyroidism: mechanistic insights, clinical evidence, and translational perspectives A large cross-sectional analysis found that people with higher dietary selenium intake had lower odds of subclinical hypothyroidism, though the researchers cautioned that the relationship needs confirmation with better methods.31PubMed Central. Dietary Selenium Intake and Subclinical Hypothyroidism: A Cross-Sectional Analysis of the ELSA-Brasil Study
The SETI study, a clinical trial of selenium supplementation in patients with autoimmune-related subclinical hypothyroidism, found that a short course of selenomethionine normalized TSH levels in half of participants, and the benefit persisted six months after they stopped taking it. The TSH-lowering effect did not appear to work through changes in thyroid antibody levels, and the researchers speculated that selenium’s antioxidant and anti-inflammatory properties might be responsible.32PubMed. Selenium supplementation in patients with subclinical hypothyroidism affected by autoimmune thyroiditis: Results of the SETI study These results are intriguing but come from a single trial. Selenium supplementation is not part of standard guidelines, and taking too much selenium carries its own toxicity risks. If you are considering it, doing so under medical supervision and within recommended intake limits is the sensible approach.
Screening the General Population
Whether healthy adults should be routinely screened for subclinical hypothyroidism remains debated. Pregnant women represent the strongest case for universal screening, as noted above, and several economic models support it. For elderly adults not during pregnancy, a decision-analysis model found that screening every three to five years could be worthwhile from a cost-effectiveness standpoint, with the benefit being greater in women than in men due to the higher prevalence of thyroid dysfunction in women.33PubMed. Cost effectiveness of screening for subclinical hypothyroidism in the elderly. A decision-analytical model In practice, most thyroid societies recommend targeted testing in people with risk factors, symptoms, or a family history rather than blanket population screening. The exception is pregnancy, where the cost-benefit math clearly favors checking everyone.